Table 2. Clinical characteristics and... | American Society of Hematology

Table 2.

Clinical characteristics and cytogenetic findings of patients included in the cohort to determine the significance of differential MLL, DOX6, FLI1, and ETS1 expression in normal marrow, MDS, and AML

Case no.	Age, y	Sex	Diagnosis*	Karyotype†
1	64	M	MDS/RAEB	45∼46, XY, -5, -7, -14, -16, -19, -20, -21, +6∼7mar
2	69	F	MDS/RAEB-T	46,XX
3	61	M	MDS/RAEB	46,XY
4	69	M	MDS/RA	46,XY
5	70	F	MDS/RAEB	46,XX
6	78	M	MDS/RA	46,XY
7	48	M	MDS/RAEB	46,XY
8	76	F	MDS/RAEB-T	46,XX,der(3)t(3;?)(q21;?),t(9;22)(q34;q11.2)
9	55	F	MDS/RA	46,XX
10	36	M	MDS/RA	46,XY
11	38	F	MDS/RA	46,XX
12	71	F	AML M2	46,XX
13	78	F	sAML	46,XX
14	51	M	AML M1	47,XY,+13
15	78	F	AML M0	46,X,add(X)(p2?2),del(20)(q11.2)
16	76	F	AML M2	47,XX,i(8q),+der(8)t(1;8)(q12;p23)
17	79	M	AML M4	48∼50,XY,del(5)(q31q33), -12, -13, -14, -16, -18, -20, -21, +9∼11mar
18	68	M	AML M5	46,XY
19	45	F	AML M1	46,XX
20	45	F	AML M4	46,XX,add(16)(q23-24)
21	64	M	AML M1	46,XY
22	66	F	AML M2	46,XX

Case no.	Age, y	Sex	Diagnosis*	Karyotype†
1	64	M	MDS/RAEB	45∼46, XY, -5, -7, -14, -16, -19, -20, -21, +6∼7mar
2	69	F	MDS/RAEB-T	46,XX
3	61	M	MDS/RAEB	46,XY
4	69	M	MDS/RA	46,XY
5	70	F	MDS/RAEB	46,XX
6	78	M	MDS/RA	46,XY
7	48	M	MDS/RAEB	46,XY
8	76	F	MDS/RAEB-T	46,XX,der(3)t(3;?)(q21;?),t(9;22)(q34;q11.2)
9	55	F	MDS/RA	46,XX
10	36	M	MDS/RA	46,XY
11	38	F	MDS/RA	46,XX
12	71	F	AML M2	46,XX
13	78	F	sAML	46,XX
14	51	M	AML M1	47,XY,+13
15	78	F	AML M0	46,X,add(X)(p2?2),del(20)(q11.2)
16	76	F	AML M2	47,XX,i(8q),+der(8)t(1;8)(q12;p23)
17	79	M	AML M4	48∼50,XY,del(5)(q31q33), -12, -13, -14, -16, -18, -20, -21, +9∼11mar
18	68	M	AML M5	46,XY
19	45	F	AML M1	46,XX
20	45	F	AML M4	46,XX,add(16)(q23-24)
21	64	M	AML M1	46,XY
22	66	F	AML M2	46,XX

RA indicates refractory anemia; sAML, secondary AML.

Disease phenotype according to the French-American-British classification.

†

Dominant clonal aberration.

View Large

This Feature Is Available To Subscribers Only